Evolving pharmacotherapies for the treatment of metastatic melanoma.
Publication
, Journal Article
Salama, AKS
Published in: Clin Med Insights Oncol
2013
Metastatic melanoma remains a difficult disease to treat, and long term survivors are rare. Over the past few years, however, breakthroughs in both immunotherapy as well as targeted agents have had a tremendous impact on patients diagnosed with this disease. This review summarizes recent advances in systemic therapies for melanoma, including immune modulators directed against cytotoxic T lymphocyte associated antigen-4 (CTLA-4) and programmed death-1 (PD-1), as well as a number of targeted agents. These approaches hold great promise as the landscape of therapeutic options for advanced melanoma continues to evolve.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Clin Med Insights Oncol
DOI
ISSN
1179-5549
Publication Date
2013
Volume
7
Start / End Page
137 / 149
Location
United States
Citation
APA
Chicago
ICMJE
MLA
NLM
Salama, A. K. S. (2013). Evolving pharmacotherapies for the treatment of metastatic melanoma. Clin Med Insights Oncol, 7, 137–149. https://doi.org/10.4137/CMO.S9565
Salama, April K. S. “Evolving pharmacotherapies for the treatment of metastatic melanoma.” Clin Med Insights Oncol 7 (2013): 137–49. https://doi.org/10.4137/CMO.S9565.
Salama AKS. Evolving pharmacotherapies for the treatment of metastatic melanoma. Clin Med Insights Oncol. 2013;7:137–49.
Salama, April K. S. “Evolving pharmacotherapies for the treatment of metastatic melanoma.” Clin Med Insights Oncol, vol. 7, 2013, pp. 137–49. Pubmed, doi:10.4137/CMO.S9565.
Salama AKS. Evolving pharmacotherapies for the treatment of metastatic melanoma. Clin Med Insights Oncol. 2013;7:137–149.
Published In
Clin Med Insights Oncol
DOI
ISSN
1179-5549
Publication Date
2013
Volume
7
Start / End Page
137 / 149
Location
United States